Phio Pharmaceuticals
Phio’s proprietary RNA interference (RNAi) technology makes immune cells more effective in killing tumor cells.
Launch date
Employees
Market cap
€2.6m
Enterprise valuation
(€5m) (Public information from Sep 2024)
Share price
$3.55 PHIO
Marlborough Massachusetts (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 50.0m | 75.0m |
% growth | - | - | - | - | - | - | 50 % |
EBITDA | - | (8.7m) | (13.5m) | (11.5m) | (10.4m) | - | - |
Profit | - | (8.8m) | (13.3m) | (11.5m) | (10.8m) | (9.6m) | 47.7m |
% profit margin | - | - | - | - | - | (19 %) | 64 % |
EV / revenue | - | - | - | - | - | 0.1x | 0.0x |
EV / EBITDA | - | -1.8x | -1.0x | -0.4x | -0.2x | - | - |
R&D budget | - | 4.4m | 8.9m | 7.0m | 6.3m | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | $2.0m | Post IPO Equity |
* | N/A | $4.0m | Post IPO Equity |
* | N/A | $2.8m | Post IPO Equity |
* | $621k | Post IPO Equity | |
* | N/A | $3.1m | Post IPO Equity |
Total Funding | €27.9m |